Integrative Training Program for Pediatric Sickle Cell Pain

Who May Qualify: - Provision of signed and dated willing to sign a consent form form for adolescents 18 years old and caregivers' participation - For children \<18, informed assent and parental willing to sign a consent form to participate in the study - Willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study - Males and females; Ages 12-18 years for adolescents; no age limitations for caregivers - Documented diagnosis of sickle cell disease (any genotype) for adolescents - Adolescent scores at least 3 on the Pediatric Pain Screening Tool - Adolescent reports typical pain intensity in the past week at least 4 on a 0-10 cm Visual Analog Scale - Adolescent on stable disease-modifying treatments, if applicable (e.g., hydroxyurea, glutamine, voxelotor, crizanlizumab) as defined by not newly initiated or significantly increased dosages (mg/kg) in the past 3 months - Speak and read English Who Should NOT Join This Trial: - An adolescent has comorbid medical conditions typically associated with pain but unrelated to SCD (e.g., rheumatologic disorders or inflammatory bowel disease) - Adolescent has undergone genetic or hematopoietic stem cell therapy - Presence of a condition(s) or diagnosis, either physical or psychological, or physical exam finding that precludes participation - Adolescents receiving active treatment (e.g., weekly appointments with a provider) for nonpharmacological therapies (e.g., structured behavioral pain management, physical therapy, or acupuncture program) that overlap with the active phase of the study intervention Always talk to your doctor about whether this trial is right for you.